कंपनी का अवलोकन
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of therapeutics and pharmaceutical products across the People's Republic of China, the United States, and international markets. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which focuses on creating innovative biological treatments. This specific operational scope suggests a strategic approach to leveraging global markets for its product pipeline. As of the latest data, the company possesses a market capitalization of $11.85M and generated annual revenue of $26.85M while employing a workforce of 233 individuals. These financial metrics indicate that CASI operates with a relatively small market capitalization relative to its revenue generation, a characteristic often found in early-stage biotechnology firms where cash flow dynamics differ significantly from mature corporations. The scale of operations, defined by a market cap under $15 million, places the company in a niche segment of the healthcare industry where valuation is driven more by pipeline potential than by established profitability.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $26.85M, yet this revenue generated a net income of -$49,385,000, revealing a significant structural gap where expenses substantially exceeded earnings before interest and taxes. The EBITDA for the period stood at -$42,272,500, further highlighting the heavy cost structure typical of biotechnology development phases where research and operational costs are not immediately offset by sales. While the company maintains a cash position of $4.68M, this liquidity is contrasted sharply against total debt obligations of $18.86M, indicating a net cash deficit situation that requires careful capital management. The absence of a reported Free Cash Flow figure suggests that cash burn rates are high enough to preclude standard cash flow analysis, limiting flexibility in capital allocation. Margin analysis shows a Gross Margin of 35.8%, which is positive for a biotech firm but is overwhelmed by an Operating Margin of -333.1% and a Profit Margin of -184.0%. These deeply negative margins indicate that operating expenses are many times larger than the gross profit generated, a common challenge for companies scaling up clinical trials or commercialization efforts. Regarding return metrics, the Return on Equity is listed as N/A due to the lack of positive equity returns, while the Return on Assets stands at -61.8%, reflecting the asset-heavy nature of the business relative to its earnings performance. The Current Ratio is reported at 0.30, a figure well below the standard threshold of 1.0, which signals potential challenges in meeting short-term obligations with available liquid assets.
मूल्यांकन आकलन
Valuation multiples for CASI present unique characteristics due to its lack of consistent earnings; the Trailing Twelve Month P/E Ratio is N/A, while the Forward P/E is calculated at -0.36, implying that expected future earnings are anticipated to be negative or that the current price structure does not reflect positive earnings growth. The Price to Book ratio is recorded at -0.55, a negative figure that typically indicates a market valuation below the company's book value, often seen in distressed or highly speculative biotechnology assets. Additionally, the Price to Sales ratio stands at 0.44, suggesting the market values the company at less than half of its annual revenue, while the EV/EBITDA multiple is -0.71, further reinforcing the negative earnings profile. In terms of trading range, the stock has fluctuated between a 52-Week High of $3.09 and a 52-Week Low of $0.74, with the current trading environment reflecting a price point that requires calculation against these bounds to determine precise positioning relative to recent highs. The Beta value is 0.89, indicating that the stock's price volatility is slightly lower than the broader market index, suggesting somewhat less sensitivity to general market swings compared to high-beta biotechnology peers. These metrics collectively paint a picture of a company valued on cash and potential rather than established profitability or traditional earnings multiples.
Growth & Income
The company's growth trajectory is currently contractionary, with Revenue Growth (YoY) at -60.5% and Earnings Growth (YoY) listed as N/A due to negative earnings. The absence of positive earnings growth makes direct comparison to revenue decline difficult, but the negative revenue trend implies a shrinking top line that impacts overall business scale. Regarding income generation, the company does not distribute dividends to shareholders, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This zero payout ratio is consistent with the company's financial strategy of reinvesting all available capital, including its $4.68M cash reserve, into research and development to sustain its therapeutic pipeline rather than providing immediate returns to investors. Consequently, the overall growth and income profile is defined by significant revenue contraction and a lack of dividend income, positioning the stock as a pure-play speculative vehicle reliant on future product approvals or commercial success to reverse current financial trends.